TENX

Tenax Therapeutics, Inc. (TENX) ESG Analysis Analysis (2026)

Invetso Score: 5.4/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.0 (Moderate)

TENX provides no disclosed R&D intensity in the supplied metrics, limiting evidence of peer-leading product stewardship or lower-impact innovation versus medtech peers.

The absence of reported gross profit margin and FCF margin in the provided data reduces visibility into resource efficiency, leaving its environmental cost discipline harder to assess than peers with fuller disclosure.

No direct emissions, energy, waste, or supply-chain environmental metrics were provided, so TENX cannot be shown to outperform peers on operational footprint management.

Relative to larger medtech peers with more extensive sustainability reporting, TENX appears disclosure-light, which constrains confidence in its environmental positioning rather than proving a structural disadvantage.

Social

Score:

The provided metrics show no stock-based compensation burden, which can support employee alignment, but this is a limited social indicator versus peers with broader workforce disclosures.

TENX’s lack of supplied data on safety, turnover, diversity, or patient outcomes makes its social profile less verifiable than peers that report these material healthcare metrics.

In a regulated medical-device context, limited disclosure on quality and adverse-event management weakens evidence of stronger stakeholder protection relative to better-reporting peers.

Overall social positioning appears roughly average because the available information shows no clear labor or governance-related social strain, yet also no demonstrated peer advantage.

Governance

Score:

A debt-to-equity ratio of zero suggests a conservative capital structure, which can reduce creditor pressure and governance complexity versus more leveraged peers.

Net debt to EBITDA of 1.79 indicates manageable leverage, supporting financial discipline relative to peers with heavier balance-sheet risk.

The absence of reported stock-based compensation to revenue suggests limited dilution pressure, which is favorable versus peers with more aggressive equity compensation.

However, the provided data do not cover board independence, audit quality, or controversy history, so governance strength is supported mainly by balance-sheet conservatism rather than full oversight evidence.

Overall Score

Score:

TENX appears broadly middle-of-the-pack on ESG because conservative leverage and limited dilution are offset by sparse disclosure on the most material environmental and social indicators.

Score Driver: Sparse ESG Disclosure Limits Evidence Of Peer-Leading Positioning Across The Most Material Factors.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Tenax Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →